



Press Release

## Half-year Report on Poxel's Liquidity Agreement with Oddo Corporate Finance

**Lyon, France, July 28, 2015** - POXEL (Euronext – POXEL - FR0012432516), an independent French biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, announced today that under the liquidity agreement entrusted by Poxel to Oddo Corporate Finance, the following resources were listed on the liquidity account as of June 30, 2015:

- 12,116 shares of Poxel and
- 126,570.97 € in cash.

As a reminder, on the occasion of this agreement set up in March 2015, the resource of € 250,000.00 in cash was listed in the liquidity account.

### About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japanese subjects. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, [www.poxel.com](http://www.poxel.com))

### Contacts

**Investor relations / Media - EU/US**  
MacDougall Biomedical Communications  
Gretchen Schweitzer or Anca Alexandru  
[aalexandru@macbiocom.com](mailto:aalexandru@macbiocom.com)  
+ 49 89 2424 3494

**Investor relations / Media - France**  
NewCap  
Florent Alba/Nicolas Mériegeau  
[poxel@newcap.fr](mailto:poxel@newcap.fr)  
+ 33 1 44 71 98 55